



TA* p63 (E-20): sc-7254

BACKGROUND

The p53 gene is a widely studied anti-oncogene, or tumor suppressor gene. The p53 gene product can act as a negative regulator of cell growth in response to DNA damage. Mutations and allelic loss of the p53 gene have been associated with malignant transformation in a wide variety of human tumors. p53 shares considerable sequence similarity with p73, a gene that maps to a region in chromosome 1 that is frequently deleted in neuroblastomas. However, p73 does not appear to be activated by DNA damaging agents. Another protein that has sequence homology to p53, designated KET, is expressed during embryonic development and in certain adult tissues, and may play a role in development and differentiation.

REFERENCES

1. Lane, D.P., et al. 1990. p53: oncogene or anti-oncogene? *Genes and Dev.* 4: 1-8.
2. Malkin, D., et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 250: 1233-1238.
3. Kastan, M.B., et al. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell* 71: 587-597.
4. Jost, C.A., et al. 1997. p73 is a human p53-related protein that can induce apoptosis. *Nature* 389: 191-194.
5. Kaghad, M., et al. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* 90: 809-819.
6. Schmale, H., et al. 1997. A novel protein with strong homology to the tumor suppressor p53. *Oncogene* 15: 1363-1367.

CHROMOSOMAL LOCATION

Genetic locus: TP73L (human) mapping to 3q28; Trp63 (mouse) mapping to 16 B1.

SOURCE

TA* p63 (E-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of TA* p63 α of rat origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-7254 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

APPLICATIONS

TA* p63 (E-20) is recommended for detection of TA* p63 α , β , and γ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for p63 siRNA (h): sc-36161 and p63 siRNA (m): sc-36162.

Molecular Weight of TA* p63: 85 kDa.

Positive Controls: normal bladder, normal colon, or colon carcinoma.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.